Biomx Ltd (PHGE) Stock Price, Quote & News

Company Profile

BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from...

Industry: Biotechnology

Sector: Healthcare

Website: www.biomx.com

Address:

850 New Burton Road, Suite 201, Dover, United States

DJTEM Apr. 5 at 3:54 PM

$PHGE Happy Easter from the Goldie school. Here we are waiting the pop till 11/12$.

0 · Reply

toffernelson Apr. 2 at 8:30 PM

$PHGE Good to see recovery here.

0 · Reply

Moon1987 Apr. 2 at 3:27 PM

$ABVE $DFNS $AMZE $PHGE this my friend is 10000% correct . That was his response yet on whatsapp he was telling me at 7$ to buy a boatload on NUKK cos he speaks to Menny and its going to 25$ next week, same thing he said with AMZE and he tried backing it by showing a screenshot of Aaron Day the CEO resharing his twitter post to validate his claims lol. PHGE is his current pump. What a horrible impotent man he is. lol

1 · Reply

Maverick11 Apr. 2 at 3:25 PM

$PHGE $SWMR $PHGE - retail shorts have stepped in here … close the DFSL deal and announce the next/real one …

1 · Reply

Moon1987 Apr. 2 at 3:14 PM

$ABVE $DFNS $PHGE $AMZE hahah our friend Neil Bhatia is at it again. Im sure he is in bed with the Israelis, every single company near enough he pumps Israeli stock and they drop in value by 70% or more. DFNS at 7$ he saying its going 25$ buy more!! I have 1mn shares. lol. AMZE at 0.38c , its going to $3 buy more i have 800,000 shares, between me and my friends we own half the float”, its now 0.13c. Now PHGE he was shouting it out at 6$ and its at 3$ something. If you oust him on these forums him and his friend Toffer Nelson block you. They only like retail fools falling for their bull, anyone with brains they despise as they cannot fool them. Horrible men. Stay Away!!!

3 · Reply

Blind_Trader_ Apr. 2 at 2:49 PM

$DFNS $PHGE $ABVE $AMZE @toffernelson Persona non grata

0 · Reply

OrangeDirt Apr. 2 at 1:23 PM

$PHGE avoid anything Israel

0 · Reply

DJTEM Apr. 2 at 10:15 AM

$PHGE bullish again. 12$ is the target very soon. Goldie

2 · Reply

RocketCityRetai1 Apr. 1 at 10:08 PM

$PHGE I’m buying a little market close May 13th and building from there. When is earnings?

0 · Reply

focafoca99 Apr. 1 at 7:45 PM

$PHGE is using an option structure to line up a potential purchase of DFSL, an anti-drone detection company, once the underlying Israeli deal closes.

0 · Reply

BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

Mar 30, 2026, 9:28 AM EDT - 6 days ago

BiomX Adds Former Mossad Deputy to Advisory Board

Mar 27, 2026, 4:30 PM EDT - 8 days ago

BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

Mar 26, 2026, 8:48 AM EDT - 10 days ago

BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

Mar 19, 2026, 9:15 AM EDT - 17 days ago

BiomX CEO Issues Letter to Stockholders

Mar 9, 2026, 9:00 AM EDT - 27 days ago

BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

Jan 27, 2026, 1:41 PM EST - 2 months ago

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

Dec 29, 2025, 8:00 AM EST - 3 months ago

BiomX Announces $3.0 Million Private Placement

Nov 26, 2025, 1:23 PM EST - 4 months ago

BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review

Nov 25, 2025, 4:40 PM EST - 4 months ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

Nov 12, 2025, 7:30 AM EST - 5 months ago

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

Oct 17, 2025, 8:30 AM EDT - 6 months ago

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

Aug 19, 2025, 8:19 AM EDT - 8 months ago

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

Aug 13, 2025, 6:30 AM EDT - 8 months ago

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Aug 6, 2025, 8:30 AM EDT - 8 months ago

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Jul 14, 2025, 9:00 AM EDT - 9 months ago

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Jul 8, 2025, 8:30 AM EDT - 9 months ago

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

May 19, 2025, 10:02 AM EDT - 11 months ago

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025, 6:30 AM EDT - 11 months ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 8, 2025, 7:00 AM EDT - 11 months ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 1, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025, 6:30 AM EDT - 1 year ago

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025, 12:35 PM EDT - 1 year ago

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Nov 14, 2024, 6:30 AM EST - 1 year ago

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024, 12:20 PM EST - 1 year ago

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 10:55 AM EDT - 1 year ago

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Explode In Q3

DXCM EW

Jul 29, 2024, 7:00 AM EDT - 1 year ago

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Jul 10, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

May 30, 2024, 4:50 PM EDT - 2 years ago

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

May 30, 2024, 7:00 AM EDT - 2 years ago

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

May 21, 2024, 6:30 AM EDT - 2 years ago

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 15, 2024, 7:00 AM EDT - 2 years ago

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Apr 18, 2024, 8:00 AM EDT - 2 years ago

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Apr 3, 2024, 6:30 AM EDT - 2 years ago

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:30 AM EDT - 2 years ago

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Mar 18, 2024, 6:30 AM EDT - 2 years ago

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Mar 6, 2024, 7:30 AM EST - 2 years ago

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Jan 4, 2024, 8:00 AM EST - 2 years ago

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Nov 30, 2023, 4:15 PM EST - 2 years ago

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Nov 29, 2023, 6:30 AM EST - 2 years ago

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

DJTEM Apr. 5 at 3:54 PM

$PHGE Happy Easter from the Goldie school. Here we are waiting the pop till 11/12$.

0 · Reply

toffernelson Apr. 2 at 8:30 PM

$PHGE Good to see recovery here.

0 · Reply

Moon1987 Apr. 2 at 3:27 PM

1 · Reply

Maverick11 Apr. 2 at 3:25 PM

$PHGE $SWMR $PHGE - retail shorts have stepped in here … close the DFSL deal and announce the next/real one …

1 · Reply

Moon1987 Apr. 2 at 3:14 PM

3 · Reply

Blind_Trader_ Apr. 2 at 2:49 PM

$DFNS $PHGE $ABVE $AMZE @toffernelson Persona non grata

0 · Reply

OrangeDirt Apr. 2 at 1:23 PM

$PHGE avoid anything Israel

0 · Reply

DJTEM Apr. 2 at 10:15 AM

$PHGE bullish again. 12$ is the target very soon. Goldie

2 · Reply

RocketCityRetai1 Apr. 1 at 10:08 PM

$PHGE I’m buying a little market close May 13th and building from there. When is earnings?

0 · Reply

focafoca99 Apr. 1 at 7:45 PM

$PHGE is using an option structure to line up a potential purchase of DFSL, an anti-drone detection company, once the underlying Israeli deal closes.

0 · Reply

Tradelyfe Apr. 1 at 3:52 PM

$PHGE heavy heavy dilution

0 · Reply

Tradelyfe Apr. 1 at 3:46 PM

$PHGE yes, but toffernelson is bullish and says everything is fine 😂

2 · Reply

Blind_Trader_ Apr. 1 at 2:25 PM

$DFNS $AMZE $PHGE the problem here is that we keep calling them out, but if they really are short, it only plays into their hands. either way we cant win...

0 · Reply

Sonofabeachery Apr. 1 at 2:23 PM

$AMZE pulling for you guys. A lot of pumpers on this bagged you and then ran it down. $PHGE $DFNS that Neil should be in jail

1 · Reply

Tradelyfe Apr. 1 at 2:12 PM

$PHGE sooo what’s the news? Now unhalted

0 · Reply

simplifocused Apr. 1 at 1:44 PM

$PHGE laughing bears about to be smoked nfa

0 · Reply

RocketCityRetai1 Mar. 31 at 10:45 PM

$PHGE did they pull 2 rugs in a week?

0 · Reply

ASseenONtv Mar. 31 at 9:00 PM

$PHGE Probably another company in line for a class action lawsuit.

0 · Reply

Tradelyfe Mar. 31 at 8:59 PM

$DFNS tofferneson is still bullish till eternity lmao same with $PHGE that dumoed 40% after his morning posts there today 😂😳😂

0 · Reply

ASseenONtv Mar. 31 at 8:57 PM

$PHGE Lots of inflating then in step, lots of deflating.

0 · Reply

ASseenONtv Mar. 31 at 8:56 PM

$PHGE is BNGO in disguise

0 · Reply

bigguy123 Mar. 31 at 8:22 PM

$PHGE All of these symbols were huge winners for me . maybe you just missed em abve .50 to 5.50 nukk 3 to 80 phge 3 to 8 My only loser was dgxx 8 to 2

0 · Reply

Market Cap	5.83M
Revenue (ttm)	0.00
Net Income (ttm)	-36.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	61,500
Avg Vol	1,236,326
Day's Range	N/A - N/A
Shares Out	1.59M
Stochastic %K	19%
Beta	1.69
Analysts	Hold
Price Target	$26.00